Datopotamab deruxtecan failed to extend OS vs. chemotherapy for adults with advanced breast cancer, according to the agent’s manufacturer.
Datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo) is a TROP2-directed antibody-drug conjugate that has demonstrated antitumor activity among pretreated patients with metastatic hormone receptor-positive, HER2-negative breast cancer.
The randomized phase 3 TROPION-Breast01 trial included 732 adults with inoperable or metastatic hormone receptor-positive, HER2-low or HER2-negative breast cancer. Study participants either experienced disease progression